Should You Buy Medtronic Stock as Its Hugo Surgical Robot Gains Ground?
The company is in the process of expanding the uses for its Hugo Surgical System and expanding its revenue base.
Overview
Shares of Medtronic (NYSE: MDT) are down more than 3% this year, presenting a compelling opportunity for savvy, growth-oriented investors.
The healthcare company, known for its medical devices, is seeing significant gains in its Hugo robotic-assisted surgery (RAS) system. Just five years after the first Hugo procedure, the Hugo is eroding the edge that industry leader Intuitive Surgical (NASDAQ: ISRG) has long held.
Details
Medtronic got approval from the Food and Drug Administration (FDA) to use the Hugo in urological procedures last December and in June submitted several new regulatory filings to the FDA to broaden Hugo's use in general and gynecological surgeries.
Source
Originally published at www.fool.com.